Fairpointe Capital’s Marrone Bio Innovations, Inc. MBII Stock Holding History

Fairpointe Capital’s Portfolio MBII Stock Details MBII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$1.38M	Buy	661,100 +47,200	+8%	+$98K	2.09%	10
2020 Q4	$767K	Hold	613,900	–	–	0.14%	57
2020 Q3	$749K	Hold	613,900	–	–	0.12%	53
2020 Q2	$718K	Buy	613,900 +25,000	+4%	+$23.1K	0.1%	58
2020 Q1	$481K	Buy	588,900 +123,500	+27%	+$131K	0.07%	60
2019 Q4	$470K	Buy	465,400 +50,000	+12%	+$60.6K	0.04%	65
2019 Q3	$586K	Buy	415,400 +124,400	+43%	+$176K	0.03%	60
2019 Q2	$436K	Buy	291,000 +100,000	+52%	+$155K	0.02%	69
2019 Q1	$292K	Buy	191,000 +58,760	+44%	+$89.7K	0.01%	71
2018 Q4	$194K	Buy	+132,240	New	+$203K	0.01%	80

Other funds holding MBII

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fairpointe Capital's MBII Position: Q1 2021 in Review

Fairpointe Capital increased its Marrone Bio Innovations, Inc. (MBII) stake by 7.7% in Q1 2021, buying an estimated $98K and bringing the position to 661,100 shares worth $1.38M. The position accounts for 2.09% of the portfolio, ranked #10.

Fairpointe Capital first reported a position in MBII in Q4 2018 and has held it in 10 quarters since. 74 funds tracked by Wall St. Rank hold MBII as of Q1 2021.

Fairpointe Capital held 661,100 shares of Marrone Bio Innovations, Inc. worth $1.38M as of Q1 2021.
Fairpointe Capital bought 47,200 Marrone Bio Innovations, Inc. shares in Q1 2021, an estimated $98K.
Marrone Bio Innovations, Inc. made up 2.09% of Fairpointe Capital's portfolio in Q1 2021, its #10 holding.
Fairpointe Capital first reported a position in Marrone Bio Innovations, Inc. in Q4 2018 and has held it in 10 quarters since.
74 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.